These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 21900289)

  • 1. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
    Pocock SJ; Ariti CA; Collier TJ; Wang D
    Eur Heart J; 2012 Jan; 33(2):176-82. PubMed ID: 21900289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
    Solomon SD; Dobson J; Pocock S; Skali H; McMurray JJ; Granger CB; Yusuf S; Swedberg K; Young JB; Michelson EL; Pfeffer MA;
    Circulation; 2007 Sep; 116(13):1482-7. PubMed ID: 17724259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.
    Kotalik A; Eaton A; Lian Q; Serrano C; Connett J; Neaton JD
    Clin Trials; 2019 Dec; 16(6):626-634. PubMed ID: 31389723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the most appropriate components for a composite clinical trial outcome.
    Bethel MA; Holman R; Haffner SM; Califf RM; Huntsman-Labed A; Hua TA; McMurray J
    Am Heart J; 2008 Oct; 156(4):633-40. PubMed ID: 18926145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.
    Dong G; Li D; Ballerstedt S; Vandemeulebroecke M
    Pharm Stat; 2016 Sep; 15(5):430-7. PubMed ID: 27485522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
    Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
    Eur J Heart Fail; 2007 May; 9(5):510-7. PubMed ID: 17317308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
    Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
    Castagno D; Skali H; Takeuchi M; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pfeffer MA; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2012 May; 59(20):1785-95. PubMed ID: 22575317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S; Wang D; Wilhelmsen L; Hennekens CH
    Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A win ratio approach to comparing continuous non-normal outcomes in clinical trials.
    Wang D; Pocock S
    Pharm Stat; 2016 May; 15(3):238-45. PubMed ID: 26970432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    McMurray JJ; Andersson FL; Stewart S; Svensson K; Solal AC; Dietz R; Vanhaecke J; van Veldhuisen DJ; Ostergren J; Granger CB; Yusuf S; Pfeffer MA; Swedberg K
    Eur Heart J; 2006 Jun; 27(12):1447-58. PubMed ID: 16754631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial.
    Abdalla S; Montez-Rath ME; Parfrey PS; Chertow GM
    Contemp Clin Trials; 2016 May; 48():119-24. PubMed ID: 27080930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
    Ariti CA; Cleland JG; Pocock SJ; Pfeffer MA; Swedberg K; Granger CB; McMurray JJ; Michelson EL; Ostergren J; Yusuf S
    Am Heart J; 2011 Nov; 162(5):900-6. PubMed ID: 22093207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.